Version 3 2024-06-17, 13:57Version 3 2024-06-17, 13:57
Version 2 2024-06-03, 22:15Version 2 2024-06-03, 22:15
Version 1 2015-04-30, 12:26Version 1 2015-04-30, 12:26
journal contribution
posted on 2024-06-17, 13:57authored byAF Ralph, B Ager, ML Bell, Ian CollinsIan Collins, L Andrews, K Tucker, N O'Reilly, K Phillips, P Butow
Purpose
Selective Estrogen Receptor Modulators (SERMs) reduce the risk of breast cancer for women at increased risk by 38%. However, uptake is extremely low and the reasons for this are not completely understood. The aims of this study were to utilize time trade-off methods to determine the degree of risk reduction required to make taking SERMs worthwhile to women, and the factors associated with requiring greater risk reduction to take SERMs.
Methods
Women at increased risk of breast cancer (N = 107) were recruited from two familial cancer clinics in Australia. Participants completed a questionnaire either online or in pen and paper format. Hierarchical multiple linear regression analysis was used to analyze the data.
Results
Overall, there was considerable heterogeneity in the degree of risk reduction required to make taking SERMs worthwhile. Women with higher perceived breast cancer risk and those with stronger intentions to undergo (or who had undergone) an oophorectomy required a smaller degree of risk reduction to consider taking SERMs worthwhile.
Conclusion
Women at increased familial risk appear motivated to consider SERMs for prevention. A tailored approach to communicating about medical prevention is essential. Health professionals could usefully highlight the absolute (rather than relative) probability of side effects and take into account an individual’s perceived (rather than objective) risk of breast cancer.